Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]
Pharmaceuticals, 2021 Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore,
Nina Vodošek Hojs +5 more
doaj +6 more sources
Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]
Endocrine and Metabolic ScienceChronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe +5 more
doaj +5 more sources
Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD [PDF]
Kidney International ReportsIntroduction: Mineralocorticoid receptor antagonists (MRAs) have reemerged as a key strategy for cardiorenal risk reduction after the success of finerenone in large trials.
Berfu Korucu +4 more
doaj +2 more sources
Intrarenal Hemodynamic Mechanisms of Kidney Protection by Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]
Endocrinology and MetabolismNonsteroidal mineralocorticoid receptor antagonists (nsMRAs), especially finerenone, have shown significant cardiorenal benefits in patients with chronic kidney disease (CKD).
Eun Sil Koh +3 more
doaj +2 more sources
Effects of mineralocorticoid receptor antagonists on coronary microcirculation: a mini-review [PDF]
Frontiers in Cardiovascular MedicineMineralocorticoid receptor antagonists (MRAs) serve as a foundational therapies in the management of heart failure, hypertension, and chronic kidney disease.
Yu Li, Zhenhong Zhang
doaj +2 more sources
Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]
Reviews in Cardiovascular MedicineCardiovascular (CV)-kidney-metabolic (CKM) syndrome is a complex disorder characterized by the co-occurrence of CV risk factors, including chronic kidney disease (CKD), hypertension, and metabolic dysfunction, which creates a vicious cycle where one ...
Biykem Bozkurt +2 more
doaj +2 more sources
Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
Pulmonary Circulation, 2021 Abnormalities that characterize pulmonary arterial hypertension include impairment in the structure and function of pulmonary vascular endothelial and smooth muscle cells.
Divya P. Menon +10 more
doaj +1 more source
Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease [PDF]
Romanian Journal of Medical Practice, 2022 The latest treatment guidelines for patients with arterial hypertension continues to indicate as the first line therapy a minimal association between renin-angiotensin system (RAS) blockers and a thiazide-type or a thiazide-like diuretic.
Andrei Niculae +5 more
doaj +1 more source
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction
Cells, 2022 Mitral regurgitation (MR), the disruption of the mitral valve, contributes to heart failure (HF). Under conditions of volume overload, excess mineralocorticoids promote cardiac fibrosis.
Wei-Ting Chang +7 more
doaj +1 more source
New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood
Çocuk Dergisi, 2023 The purpose of the review is to summarize the current pharmacological management of chronic kidney disease (CKD) in pediatric patients and critically present emerging evidence for the use of mineralocorticoid receptor antagonists and sodium-glucose ...
Siobhan Wagner +2 more
doaj +1 more source